Clinical Experience of Tigecycline Treatment in Infections Caused by Extensively Drug-Resistant Acinetobacter spp.
- 1 December 2012
- journal article
- research article
- Published by SAGE Publications in Microbial Drug Resistance
- Vol. 18 (6) , 562-566
Abstract
Background: Tigecycline has broad spectrum antimicrobial activity and is approved for complicated intra-abdominal infections, complicated skin and soft tissue infections, and community-acquired pneumonia. There are few data on clinical experience of tigecycline in hospital-acquired pneumonia (HAP) and Acinetobacter spp. infection. Methods: A retrospective study was performed at eight hospitals in Korea from May 2009 to January 2010. Adult patients treated with tigecycline regardless of their source of infection or pathogens were enrolled. Results: Tigecycline was administered in 108 patients. Pneumonia was the most common infection (43.5%), followed by skin and soft tissue infections (20.4%). Acinetobacter baumannii was isolated from 83 patients (76.9%) accounting for 50.3% of isolated pathogens, showing a resistance rate of 67.5% to carbapenems. Superinfection was identified in 32 patients (29.6%). Pseudomonas aeruginosa was most common microorganism causing superinfection (46.9%). Overall 30-day mortality rate was 52.9%. Thirty-day mortality rate of HAP and Acinetobacter spp. infection was 60.5% and 59.4%, respectively. Conclusion: Tigecycline can be considered as an alternative therapy in patients with HAP or infections caused by Acinetobacter spp., especially extensively drug-resistant A. baumannii .Keywords
This publication has 24 references indexed in Scilit:
- Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumoniaDiagnostic Microbiology and Infectious Disease, 2010
- Tigecycline use in serious nosocomial infections: a drug use evaluationBMC Infectious Diseases, 2010
- Antimicrobial Treatment and Clinical Outcomes of Carbapenem-Resistant Acinetobacter baumannii Ventilator-Associated PneumoniaJournal of Intensive Care Medicine, 2010
- Treatment ofAcinetobacterInfectionsClinical Infectious Diseases, 2010
- Tigecycline Use in Cancer Patients With Serious InfectionsMedicine, 2009
- Late Onset Ventilator-Associated Pneumonia Due to Multidrug-Resistant Acinetobacter spp.: Experience with TigecyclineJournal of Chemotherapy, 2009
- Pandrug Resistance (PDR), Extensive Drug Resistance (XDR), and Multidrug Resistance (MDR) among Gram‐Negative Bacilli: Need for International Harmonization in TerminologyClinical Infectious Diseases, 2008
- Clinical and Microbiological Outcomes of Serious Infections with Multidrug-Resistant Gram-Negative Organisms Treated with TigecyclineClinical Infectious Diseases, 2008
- Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in SepsisChest, 1992
- Adapting a clinical comorbidity index for use with ICD-9-CM administrative databasesJournal of Clinical Epidemiology, 1992